Nominations for the 2014 award are closed.
- View the list of all past recipients.
The AACR Award for Lifetime Achievement in Cancer Research was established and first given in 2004 to honor an individual who has made significant fundamental contributions to cancer research, either through a single scientific discovery or a body of work. These contributions, whether they have been in research, leadership or mentorship, must have had a lasting impact on the cancer field and must have demonstrated a lifetime commitment to progress against cancer.
The Tenth Annual Award was presented at the AACR Annual Meeting 2013 in Washington, DC, USA (April 6-10, 2013). The recipient must be present to receive the award unless otherwise unable to do so because of health restrictions or other serious conflicts.
The recipient received an honorarium, a commemorative award, and support for the winner and a guest to attend the AACR Annual Meeting.
- Nominations may be made on behalf of individuals who are living at the time of the nomination.
- Candidates need not be members of the AACR.
- Candidates need not be currently engaged in cancer research.
- There are no restrictions with regard to race, gender, nationality, geographic location, or religious or political views.
- The award will be presented to an individual investigator.
- Institutions or organizations are not eligible for the award.
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Candidates will be considered by a Selection Committee of international cancer leaders appointed by the President of the AACR. After careful deliberations by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the award winner will be made on the basis of the candidate's significant, fundamental contributions to cancer research (whether in research, leadership or mentorship); the lasting impact of these contributions on the cancer field; and the demonstration of a lifetime commitment to progress against cancer.
American Association for Cancer Research
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
10th Annual Award Recipient
Harold L. Moses, M.D.
Professor and Chair of Cancer Biology
Hortense B. Ingram Professor of Molecular Biology
Vanderbilt-Ingram Cancer Center
Vanderbilt School of Medicine
Dr. Moses received his award during the Opening Ceremony at the AACR Annual Meeting 2013 in Washington, D.C. The ceremony was held on Sunday, April 7, 2013. Visit the AACR Annual Meeting 2013 page for more information on the Annual Meeting.
Dr. Robert C. Young is one of the country’s most respected and recognized clinical investigators and oncology leaders. He has served as the Chairman of the Board of Scientific Advisors of the National Cancer Institute, and President of American Society of Clinical Oncology, the American Cancer Society and the International Gynecologic Cancer Society
His contributions to cancer research span over 4 decades in which he has made significant contributions to the treatment of Hodgkin’s disease, lymphomas and ovarian cancer. His early focus on the neglected field of ovarian cancer research has led to a robust worldwide clinical structure of national and international cooperative group trials, substantial SPORE and DOD programs in ovarian cancer, and standardized staging and grading of the tumor.
Dr. Young’s contributions began at the Medicine Branch of the National Cancer Institute where he was part of a leadership team that demonstrated the curability of advanced Hodgkin’s disease and diffuse lymphoma with combination chemotherapy. Dr. Young rose to head the Medicine Branch of the NCI where he served for 14 years during which he trained many of the Medical Oncology leaders of today including three recent Presidents of ASCO.
At NCI, Dr. Young initiated and led a broad research program in ovarian cancer. When he began the ovarian program, there was no national or international research effort underway. At the time, the most commonly used drug for advanced ovarian cancer was the alkylating agent Melphalan which produced a median survival of 12 months and an elevated risk of second malignancies in women who did survive.
Under Dr. Young’s leadership his group developed a strategy for progress, established the first ovarian cancer cell lines, stimulated clinical trial development on national scale, characterized and standardized staging, grading, and prognostic factors and published the first randomized clinical trial establishing combination chemotherapy as the preferred treatment for advanced disease.
Dr. Young moved to be the President and CEO of Foc Chase Cancer Center and continued the ovarian cancer work where he led national clinical trials in early stage ovarian cancer which have established the standard of care and (with his colleagues Drs. Ozols and Bookman established Carboplatin and Taxol as the standard of care in advanced disease. For this body of work he and Dr. Ozols shared the Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research Numerous patients have benefited as a result of the work of Dr. Young and his colleagues.